» Articles » PMID: 38543092

Synthesis of 5-Benzylamino and 5-Alkylamino-Substituted Pyrimido[4,5-c]quinoline Derivatives As CSNK2A Inhibitors with Antiviral Activity

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Mar 28
PMID 38543092
Authors
Affiliations
Soon will be listed here.
Abstract

A series of 5-benzylamine-substituted pyrimido[4,5-c]quinoline derivatives of the CSNK2A chemical probe SGC-CK2-2 were synthesized with the goal of improving kinase inhibitor cellular potency and antiviral phenotypic activity while maintaining aqueous solubility. Among the range of analogs, those bearing electron-withdrawing ( and ) or donating () substituents on the benzyl ring as well as introduction of non-aromatic groups such as the cyclohexylmethyl () were shown to maintain CSNK2A activity. The CSNK2A activity was also retained with -methylation of SGC-CK2-2, but α-methyl substitution of the benzyl substituent led to a 10-fold reduction in potency. CSNK2A inhibition potency was restored with indene-based compound , with activity residing in the S-enantiomer (). Analogs with the highest CSNK2A potency showed good activity for inhibition of Mouse Hepatitis Virus (MHV) replication. Conformational analysis indicated that analogs with the best CSNK2A inhibition (, , and ) exhibited smaller differences between their ground state conformation and their predicted binding pose. Analogs with reduced activity (, , and ) required more substantial conformational changes from their ground state within the CSNK2A protein pocket.

Citing Articles

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

Ong H, Yang X, Smith J, Taft-Benz S, Howell S, Dickmander R Molecules. 2024; 29(17).

PMID: 39275006 PMC: 11397024. DOI: 10.3390/molecules29174158.

References
1.
Pierre F, Chua P, OBrien S, Siddiqui-Jain A, Bourbon P, Haddach M . Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2010; 54(2):635-54. DOI: 10.1021/jm101251q. View

2.
Korner R, Majjouti M, Alejandre Alcazar M, Mahabir E . Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. Viruses. 2020; 12(8). PMC: 7471983. DOI: 10.3390/v12080880. View

3.
Grygier P, Pustelny K, Nowak J, Golik P, Popowicz G, Plettenburg O . Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. J Med Chem. 2023; 66(6):4009-4024. PMC: 10041529. DOI: 10.1021/acs.jmedchem.2c01887. View

4.
Wells C, Drewry D, Pickett J, Tjaden A, Kramer A, Muller S . Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chem Biol. 2021; 28(4):546-558.e10. PMC: 8864761. DOI: 10.1016/j.chembiol.2020.12.013. View

5.
Litchfield D . Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2002; 369(Pt 1):1-15. PMC: 1223072. DOI: 10.1042/BJ20021469. View